Skip to main content
Back
CHEOF logo

Cochlear Limited

Data quality: 100%
Oversold
CHEOF
OTC Healthcare Medical - Devices
$116.81
▼ $7.15 (-5.77%)
Mkt Cap: 7.64B
Also listed as CHEOY OTC
Day Range
$116.81 $116.81
52-Week Range
$116.81 $207.71
Volume
6,995
50D / 200D Avg
$181.02 / $185.43
Prev Close
$123.96

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (627 peers)

Metric Stock Sector Median
P/E 19.6 0.3
P/B 3.9 2.9
ROE % 20.5 3.7
Net Margin % 16.6 3.8
Rev Growth 5Y % 11.8 10.0
D/E 0.1 0.2

Analyst Price Target

No analyst coverage available

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2030 $11.53
$10.93 – $12.27
 2.5 B 1
FY2029 $10.69
$10.14 – $11.38
 3.7 B 1
FY2028 $8.50
$8.06 – $9.05
 3.2 B 1

Key Takeaways

Revenue grew 11.84% annually over 5 years — strong growth
ROE of 20.52% indicates high profitability
Net margin of 16.60% shows strong profitability
Debt/Equity of 0.12 — conservative balance sheet
Generating 135.00M in free cash flow
Revenue growth is decelerating — 1Y growth trails 5Y average by 7.03%

Growth

Revenue Growth (5Y)
11.84%
Revenue (1Y)4.81%
Earnings (1Y)9.00%
FCF Growth (3Y)-28.83%

Quality

Return on Equity
20.52%
ROIC13.93%
Net Margin16.60%
Op. Margin17.33%

Safety

Debt / Equity
0.12
Current Ratio2.35
Interest Coverage36.92

Valuation

P/E Ratio
19.64
P/B Ratio3.92
EV/EBITDA18.71
Dividend Yield0.02%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 4.81% Revenue Growth (3Y) 10.01%
Earnings Growth (1Y) 9.00% Earnings Growth (3Y) 13.74%
Revenue Growth (5Y) 11.84% Earnings Growth (5Y) 4.47%
Profitability
Revenue (TTM) 2.34B Net Income (TTM) 388.90M
ROE 20.52% ROA 13.77%
Gross Margin 73.74% Operating Margin 17.33%
Net Margin 16.60% Free Cash Flow (TTM) 135.00M
ROIC 13.93% FCF Growth (3Y) -28.83%
Safety
Debt / Equity 0.12 Current Ratio 2.35
Interest Coverage 36.92 Dividend Yield 0.02%
Valuation
P/E Ratio 19.64 P/B Ratio 3.92
P/S Ratio 3.26 PEG Ratio 5.17
EV/EBITDA 18.71 Dividend Yield 0.02%
Market Cap 7.64B Enterprise Value 7.60B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 2.34B 2.24B 1.94B 1.65B 1.50B
Net Income 388.90M 356.80M 300.60M 289.10M 326.50M
EPS (Diluted) 5.93 5.43 4.56 4.40 4.93
Gross Profit 1.73B 1.67B 1.45B 1.24B 1.09B
Operating Income 406.10M 475.00M 389.50M 402.40M 370.20M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 2.83B 2.75B 2.57B 2.47B 2.44B
Total Liabilities 874.70M 904.60M 819.90M 779.40M 736.50M
Shareholders' Equity 1.95B 1.84B 1.75B 1.69B 1.70B
Total Debt 235.70M 243.70M 201.80M 253.90M 264.30M
Cash & Equivalents 275.70M 513.60M 555.50M 629.30M 609.60M
Current Assets 1.42B 1.45B 1.36B 1.33B 1.23B
Current Liabilities 602.30M 631.50M 578.00M 527.60M 402.50M

Strategy Scores

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
Value Value Investing (Warren Buffett)
#161 of 203
32

Recent Activity

Entered Value Investing (Warren Buffett)
Mar 24, 2026